BioSystems International Announces Appointment of Scientific Advisory Board.

EVRY, France -- World Renowned Specialists in Technology, Biology and Medical Science Join Biosystem's Scientific Advisory Board to Support the Company in its Biomarker Discovery and Clinical Development Programs

BioSystems International ("BSI") discovers, validates and qualifies biomarkers through partnerships with pharmaceutical, biotechnology and diagnostics companies and in-house research programs or academic cooperations. BSI merges pharmaceutical and diagnostics industry experience with leading scientific and technology expertise and know-how in separation science, proteomics, genomics and immunology.

BSI has appointed eight members to its newly-created Scientific Advisory Board (the "Board"). Originating from Austria, France, Hungary and the USA, their expertise will be key in driving the next steps in the BSI's development.

The Board comprises:

--Laszlo Fesus, M.D., Ph.D., Biochemistry and Molecular Biology University of Debrecen Medical and Health Science Center, Debrecen, Hungary

--Andras Guttman, Ph.D., D. Sci. Founder, CTO, Biosystems International Marie Curie Chair Horvath Laboratory of Bioseparation Sciences, University of Innsbruck, Austria

--William S. Hancock, Ph.D. Founder, Biosystems International, Bradstreet Chair in Bioanalytical Chemistry, Barnett Institute of Chemical and Biological Analysis, Professor, Dept. of Chemistry, Northeastern University Boston, MA, USA

--Barry Karger, Ph.D. (Chair of Technology Section) Founder, Biosystems International, James L. Waters Chair in Analytical Chemistry, Director, Barnett Institute of Chemical and Biological Analysis, Professor, Dept. of Chemistry Northeastern University, Boston, MA, USA

--Edward Rubin,MD , Ph.D. (Chair of Medical Science section) Division Director, Senior Scientist Genomics Division, Genome Sciences Department, Lawrence Berkeley National Laboratory Berkeley, CA, USA

--Laszlo Takacs, M.D., Ph.D., D. Sci. Founder, President and CSO, Biosystems International, Evry, France

--Jean Paul Thiery, Ph.D. Cell Biology Department Research Division and Head Dept Translational Research Medical Division, Institut Curie, Paris, France

--Peter Zavodszky, Ph.D. D.Sci. Member of the European Academy of Sciences and Arts, Corresponding member of the Hungarian Academy of Sciences, Research Professor and Head of the Structural Biochemistry Division at the Institute of Enzymology of the Hungarian Academy of Sciences, Professor of Biophysics at the Eotvos Lorand University, Budapest

BSI's objective is to establish a new standard in the research and discovery of biomarkers suitable for clinical development of drugs and the development of diagnostic tests. The technology platform and expertise of the Biosystems International team permits the identification of disease or pathology-specific biomarkers within a short timeframe, compatible with the constraints of drug development. Biomarkers, which make it possible to diagnose a disease, follow its progression or evaluate drug efficacy are crucial for the pharmaceutical industry. They are expected to result in a significant reduction in the cost and duration of clinical trials and improve the clinical follow-up of patients.

Acording to Laszlo Takacs, CSO & President of Biosystems Internartional: "the appointment of this new board will allow the company to shape its new clinical development strategy, mainly focused on chronic inflammatory diseases (COPD, OA) and cancer. In the coming months, BioSystems International will probably announce a couple of partnerships with established companies and academic research centers".

About BioSystems International: (http://www.biosys-intl.com)

The mission of BioSystems International is to bring biomarkers to the bedside.

BioSystems International ("BSI"), headquartered in Evry, France, operates two research laboratories in France (Genopole Evry) and in Hungary (University of Debrecen) and is currently in late-phase contract negotiations with two international pharmaceutical companies and in final phase discussions to address a partnership with a European biotechnology company.

Since it was founded in May 2004, BSI has raised EUR 3m from Societe Generale Asset Management and received a EUR 0.5m grant from the Hungarian Ministry of Education.

BSI's discovery technology and unique development methods combine high throughput monoclonal antibody technology, mass spectrometry and genome research technologies. It allows BSI to achieve the targeted and quantitative analysis of virtually all proteins in bodily fluids of patients and control subjects with the sensitivity and precision of ELISA assays. BSI builds a streamlined strategy to identify, validate and qualify the most promising biomarkers via a process that includes confirmation of clinical relevance on BSI's patient cohorts or clinical material from large Phase II and Phase III clinical trials of its partners.